Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Mallinckrodt
Novartis
Chubb
US Department of Justice
Argus Health
Cerilliant
Queensland Health
Harvard Business School
Fish and Richardson

Generated: August 23, 2017

DrugPatentWatch Database Preview

Glaxo Grp England Company Profile

« Back to Dashboard

What is the competitive landscape for GLAXO GRP ENGLAND, and what generic alternatives to GLAXO GRP ENGLAND drugs are available?

GLAXO GRP ENGLAND has one approved drug.

There are ten US patents protecting GLAXO GRP ENGLAND drugs.

There are one hundred and forty-six patent family members on GLAXO GRP ENGLAND drugs in thirty-eight countries.

Summary for Applicant: Glaxo Grp England

Patents:10
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp England
INCRUSE ELLIPTA
umeclidinium bromide
POWDER;INHALATION205382-001Apr 30, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Glaxo Grp England
INCRUSE ELLIPTA
umeclidinium bromide
POWDER;INHALATION205382-001Apr 30, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Glaxo Grp England
INCRUSE ELLIPTA
umeclidinium bromide
POWDER;INHALATION205382-001Apr 30, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Glaxo Grp England
INCRUSE ELLIPTA
umeclidinium bromide
POWDER;INHALATION205382-001Apr 30, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Glaxo Grp England
INCRUSE ELLIPTA
umeclidinium bromide
POWDER;INHALATION205382-001Apr 30, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Glaxo Grp England

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxo Grp England
INCRUSE ELLIPTA
umeclidinium bromide
POWDER;INHALATION205382-001Apr 30, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Glaxo Grp England

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,575,347Muscarinic acetylcholine receptor antagonists► Subscribe
9,045,469Muscarinic acetylcholine receptor antagonists► Subscribe
8,853,404Muscarinic acetylcholine receptor antagonists► Subscribe
9,144,571Muscarinic acetylcholine receptor antagonists► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Glaxo Grp England Drugs

Country Document Number Estimated Expiration
Taiwan200605887► Subscribe
United Kingdom0317374► Subscribe
China101272818► Subscribe
Japan5107918► Subscribe
Malaysia144753► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Glaxo Grp England Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1740177/02Switzerland► SubscribePRODUCT NAME: UMECLIDINIUM BROMID + VILANTEROL; REGISTRATION NO/DATE: SWISSMEDIC 63152 14.07.2014
2014 00052Denmark► SubscribePRODUCT NAME: UMECLIDINIUMBROMID; REG. NO/DATE: EU/1/14/922/001-003 20140428
2014038Lithuania► SubscribePRODUCT NAME: UMECLIDINIUM BROMIDIUM; REGISTRATION NO/DATE: EU/1/14/922 20140428
2014038,C1740177Lithuania► SubscribePRODUCT NAME: UMEKLIDINO BROMIDAS; REGISTRATION NO/DATE: EU/1/14/922 20140428
8 50012-2014Slovakia► SubscribePRODUCT NAME: UMEKLIDINIUMBROMID; REGISTRATION NO/DATE: EU/1/14/922/001 - EU/1/14/922/003 20140430
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Fish and Richardson
Medtronic
Deloitte
Harvard Business School
Cerilliant
US Army
Accenture
Mallinckrodt
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot